Capital reallocation from AI infrastructure to biotechnology sector anticipated

Market analysis suggests a potential shift in investment flows from AI-related hardware, such as memory and data centers, toward generative AI applications in biotechnology. The trend is predicated on the perceived growth potential of AI-driven drug discovery and healthcare innovation, though the scale and timing of this capital migration remain speculative.